At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
Esflurbiprofen Hydrogel Patchdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Safety of an Esflurbiprofen Hydrogel Patch vs. Placebo in the Local Symptomatic and Short-term Treatment of Pain in Acute Strains, Sprains or Bruises of the Extremities Following Blunt Trauma, e.g. Sports Injuries.
In Brief
A Phase 2 clinical trial evaluating Esflurbiprofen Hydrogel Patch for Soft Tissue Injuries and 4 related conditions. Completed, enrolled 200 participants across 1 site.
Detailed Summary
Objective of this study is: to determine efficacy and safety of a Esflurbiprofen Hydrogel Patch compared to placebo in patients with acute strains, sprains or bruises of the extremities following blunt trauma, e.g. sports injuries. to demonstrate that the Esflurbiprofen Hydrogel Patch is superior to placebo, and that the patch has acceptable local tolerability.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Injuries, Contusions, Strains, Sprains, Bruises
CountriesGermany
CollaboratorsClinSearch, CRM Biometrics GmbH, Clinigen, Inc.
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMay 2021
First PostedJun 2021
Primary CompletionNov 2021
Study CompletionDec 2021
TodayJul 2026
First PostedJun 1, 2021
Enrollment StartMay 20, 2021
Primary CompletionNov 9, 2021
Study CompletionDec 15, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.1 years ago
Interventions
Esflurbiprofen Hydrogel Patchdrug
Esflurbiprofen is a cyclooxygenase (COX) inhibitor